At Acadia, we remain deeply committed to providing important new therapies to patients and delivering value for our stockholders. Our Investor Center is designed to provide you with convenient access to company information.

Recent News

– Establishes co-development and co-commercialization agreement for Stoke’s SYNGAP1 preclinical program – Acadia receives exclusive worldwide licenses for two additional preclinical programs: Rett syndrome (MECP2) and undisclosed neurodevelopmental target – Combines Stoke’s TANGO research platform
SAN DIEGO --(BUSINESS WIRE)--Dec. 22, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 40 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 , at 10:30 a.m. Eastern Time , followed by a question and answer session.
- Acadia plans to resubmit its sNDA in the first quarter of 2022 - Conference call and webcast to be held today at 4:30 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Dec. 20, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it plans to resubmit its supplemental New Drug